美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.35-0.0059-0.02%19:59 EDT

成交量：1.97萬

成交額：67.75萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

創新藥概念表現活躍昂利康逼近漲停

創新藥項目報價「水漲船高」，CRO行業下半年或加速回暖

艾伯維公布CERVINO三期臨床試驗取得積極主要終點數據。

中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准

中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准

2026醫保國談將於9月5日舉行

創新藥熱浪來襲，如何把握投資機會？

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點

一品紅：痛風創新藥AR882Ⅲ期臨床達主要終點

ST人福：RFUS-949片進入II期臨床試驗研究

甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》

ETF日報(09.03)丨政策利好持續催化創新藥板塊「小非農」數據爆冷短期支撐金價

甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准

ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究

創新藥概念局部回暖

A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。

百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發

國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=11"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19691,"hourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"未開盤","change":0.1059,"latestTime":"09-16 16:00:00 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":677542.144902,"amplitude":0.012286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.27126,"aum":95274137.07126,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"volumeRatio":0.950696,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.950696,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"eps":0,"divideRate":0.007478,"volume":19691,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664383834","title":"創新藥概念表現活躍 昂利康逼近漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383834?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:47","pubTimestamp":1788486451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MEDX","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664280253","title":"創新藥項目報價「水漲船高」，CRO行業下半年或加速回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664280253","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664280253?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 06:23","pubTimestamp":1788474180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872008","title":"艾伯維公布CERVINO三期臨床試驗取得積極主要終點數據。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441323,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872828","title":"中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:42","pubTimestamp":1788439353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","IBBJ","IBBQ","PSYK","BMED","MDTX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874071","title":"中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:41","pubTimestamp":1788439284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","LABU","PSYK","BMED","BK4588","BK4585","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876096","title":"2026醫保國談將於9月5日舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876096","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664876096?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:02","pubTimestamp":1788433355,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","MEDX","BK1161","LNGR","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987512","title":"創新藥熱浪來襲，如何把握投資機會？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987512","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664987512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:14","pubTimestamp":1788430440,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpzpq4281019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","159992","BK1161","BK1574","MEDX","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875311","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875311?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年9月2日获得中国国家药品监督管理局批准磷酸芦可替尼乳膏百卢妥轻中度特应性皮炎的新药上市许可申请，并于2026年九月3日获得药品注册证书。2026年1月，百卢妥中国NDA获批，成为中国批准的首款用于白癜风治疗的外用 JAK抑制剂。继百卢妥获批白癜风适应症后，此次AD适应症NDA获批，将进一步拓展产品的临床应用空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06978","IE00BYV24P56.USD","SG9999015945.SGD","SG9999015986.USD","MEDX","00867","BK1574","IE00BGHQDM52.EUR","SG9999004220.SGD","159992","IBBQ","IE00BVYPNP33.GBP","BK1161","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","SG9999015978.USD","AD","BK1593","BK1191","LNGR","LU2488822045.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664731738","title":"一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664731738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664731738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:47","pubTimestamp":1788428833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红 发布公告，公司全资子公司广州瑞安博医药科技有限公司牵头组织开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅱ/Ⅲ期临床试验，于近日获得顶线分析数据。初步统计结果表明，AR882在痛风伴高尿酸血症参与者中表现出积极的疗效及良好的安全性，试验结果理想，达到预期目的。AR882克服了雷西纳德和苯溴马隆的缺点，能够与尿酸转运蛋白长效结合，延长抑制作用的时间，临床结果显示其药效长达24小时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","300723","BK1574","MEDX","BK1161","LNGR","BK0239","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873395","title":"一品紅：痛風創新藥AR882Ⅲ期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664873395?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:38","pubTimestamp":1788428306,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820856","title":"ST人福：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820856?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:37","pubTimestamp":1788424652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664270568?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","PSYK","IBBQ","MDTX","603087","IBBJ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820831","title":"ETF日報(09.03)丨政策利好持續催化創新藥板塊 「小非農」數據爆冷短期支撐金價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820831?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:30","pubTimestamp":1788424202,"startTime":"0","endTime":"0","summary":"国家医保局政策释放利好信号，创新药板块表现突出；美国ADP就业数据不及预期影响，黄金股相关ETF集体回升。截至收盘，恒生指数跌0.39%，报25213.31点，全日成交额1993.82亿港元；恒生科技指数跌1.08%，报4468.48点。国家医保局召开新闻发布会，发布按病种付费3.0版分组方案和技术规范，这一举措被视为对创新药板块的直接利好。因第二季净息差有所改善，信达国际短期看好内银股。中信证券表示，7月底以来，海外发达市场国债收益率普遍飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IAUI","YGLD","BAR","IAUM","CERY","GOAU","CEF","DULL","FGLD","CMDT","GDX","FGDL","GBUG","IAU","02840","AAAU","PYZ","SGDM","UGL","XLBI","BEGS","LNGR","OUNZ","06978","NANR","PALL","MGCmain","DGP","IBBQ","DZZ","GDE","SGOL","SHNY","USG","DBC","VGFPF","MEDX","GCmain","EPU","159992","JNUG","SGDJ","UYM","GDXD","BTGD","DUST","GLDM","SImain","RING","GDXY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664716827","title":"甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664716827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664716827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:29","pubTimestamp":1788424183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","IBBQ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664279758","title":"ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664279758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664279758?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:12","pubTimestamp":1788423169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)研发的RFUS-949片近日进入II期临床试验研究。试验名称：评价RFUS-949片用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂对照的疗效和安全性研究试验目的：评价RFUS-949片用于术后镇痛的疗效和安全性，探索RFUS-949片用于术后镇痛的用法用量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","PSYK","BK0188","BK0239","IBBQ","IBBJ","BMED","BK0185","MDTX","BK0070","600079","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"創新藥概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664242468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LNGR","IBBQ","BK1574","159992","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245108","title":"A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664245108?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:58","pubTimestamp":1788418691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782740?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06978","BK0216","02315","BK1191","IBBQ","MEDX","LNGR","BK1574","01477","BK1161","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","06978","159992","LNGR","MEDX","520500","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":11,"totalSize":219,"code":"91000000","status":"200"}]}}